Oragenics, Inc. Announces NYSE American Acceptance of Plan of Compliance

Company Overview - Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications targeting neurological disorders and infectious diseases, including drug candidates for mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC) [1] Compliance with NYSE American - The NYSE American has reviewed Oragenics' compliance plan submitted on May 17, 2024, and determined that the company has made a reasonable demonstration of its ability to regain compliance by October 18, 2025 [2] - During the compliance period, Oragenics will be subject to quarterly monitoring, and failure to regain compliance by the deadline may result in delisting proceedings [2][4] Recent Developments - On June 18, 2024, Oragenics received a notice from the NYSE American confirming acceptance of its plan to regain compliance with the continued listing standards [4]